Halocarbon gets FDA approval to market Sevoflurane for human anesthetic market

Published: 19-Jun-2008

Halocarbon Products Corporation, a leading worldwide producer of specialty fluorochemicals, including fluorinated inhalation anesthetics, has received approval to market the inhalation anesthetic sevoflurane, a popular and widely used anesthetic, for the US human marketplace.


Halocarbon Products Corporation, a leading worldwide producer of specialty fluorochemicals, including fluorinated inhalation anesthetics, has received approval to market the inhalation anesthetic sevoflurane, a popular and widely used anesthetic, for the US human marketplace.

"While sevoflurane is the next generation inhalation anesthetic, similar in nature to isoflurane, something Halocarbon has manufactured for a decade, sevoflurane has also been found to provide enhanced blood flow stability in patients during surgery," said Halocarbon ceo Peter Murin. "Sevoflurane is also more cost effective and efficient - patients go under faster and wake up faster."

Sevoflurane has been used as an anesthetic in both humans and animals around the world for a number of years. The company expects approval for the veterinary market in the near future.

You may also like